The diabetic macular edema market is estimated to hold a valuation of around USD 4,120.9 million in 2024. The valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034. In the forecast, the growth rate is likely to be very moderate, as the market is now quite mature and very slightly fragmented compared with several disease drug markets.
With the global diabetic population set to rise, predominantly because of increased longevity and a propensity toward obesity, the incidence of diabetic macular edema will be expected to rise proportionally. This is especially relevant in areas with increasing age demographics, in which DME is one of the comorbid diseases associated with age. Market growth is a direct reflection of an acute medical need fed by demographic realities.
Advancements in medical science are also fueling the market. Innovations in treatment methodologies, which included anti-VEGF therapy, corticosteroids, and laser surgery, have vastly altered the landscape for the treatment of DME. Continuous research, coupled with potential innovation in drug delivery systems, such as sustained-release implants and biodegradable drug carriers that are expected to increase efficacy and patient compliance respectively, will continue to usher in market growth.
Increasing the ability to access healthcare services worldwide also facilitates the growth of the market. Health infrastructure is emerging in the economies along with increasing healthcare spending, hence enhancing access to diabetic macular edema treatments.
The scenario above creates access and affordability because of government initiatives to support healthcare systems and the influence of good reimbursement scenarios that are promoting the ease of access and affordability and henceforth promoting growth in the market.
However, the market is facing challenges in the high cost of treatment and frequent clinical monitoring, which may act as restraints for the market. Underdiagnosis in low- and middle-income countries where health resources are limited further acts as a barrier to the expansion of this market.
| Attributes | Description |
|---|---|
| Estimated Global Diabetic Macular Edema Market Size (2024E) | USD 4,120.9 million |
| Projected Global Diabetic Macular Edema Market Value (2034F) | USD 4,642.9 million |
| Value-based CAGR (2024 to 2034) | 1.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Gene Therapy Can Bring a Life-long Cure for Diabetic Macular Edema
The field of treatment for diabetic macular edema is alive with the pursuit of gene therapy. Breakthrough research has been looking into the possibility of a single shot in gene therapy that would be administered once and cure diabetic macular edema forever. This will be a landmark diversion from current treatment paradigms that require control.
How Artificial Intelligence is Revolutionizing DME Diagnostics
The field of diagnosis in diabetic edema is expected to change due to the foray of AI algorithms. The new, advanced algorithms show great capabilities in the early detection of diabetic edema. It also involves the use of AI in the interpretation of data on patients in developing a personalized treatment plan for better management of the condition.
Patients with Diabetic Macular Edema: Home Monitoring Kits
The diabetic macular edema space is getting reformed rapidly with the coming in of home monitoring kits. An example of this has become part of a growing trend—home monitoring is being made simpler so that patients can proactively track changes in their vision between clinic visits. Intervention, which may prevent vision loss from occurring with diabetic macular edema, could thus be possible with this early change.
Drug Delivery Implants Improve Efficacy in the Treatment of Diabetic Macular Edema
Another promising trend for diabetic macular edema management is in the development of sustained-release drug delivery implants. These implants have a characteristic of continuous drug release over an extended period, thus offering the potential benefit of minimal injections and less burden to the patient over time.
Multifaceted Combination Therapies of DME
A greater understanding is emerging of the multifaceted nature of diabetic macular edema. With this, another major emerging trend is that of combination therapies. The combination of drugs that target different pathways of diabetic edema pathogenesis would provide an all-inclusive approach in managing the condition.
Telemedicine Now Expands Access to DME Care
Telemedicine is rapidly changing the face of accessibility to care for those patients who need diabetic macular edema. It reaches out to patients in far-off regions or with mobility limitations for consultations and follow-ups with specialists. Telemedicine has great potential to reduce this gap in DME care delivery.
Precautionary Measures are taking on a Significant Role in the Fight against DME
A significant shift in the focus of diabetic macular edema treatment is underway. Much of it is being turned from established cases toward preventive measures, which come in the shape of stiffer management protocols for diabetes and earlier intervention strategies to avoid the occurrence of DME completely.
Regenerative Medicine Turning Out to be an Option for the Reversal of DME
The future of diabetic macular edema treatment lies probably in the field of vision restoration. Studies are being carried out on the potential of regenerative medicine, including the use of stem cell therapies, to reverse DME damage and restore lost vision. This work is at a very early phase but does provide a flicker of hope to patients with diabetic edema.
Global diabetic macular edema sales have been on a rollercoaster over the period 2019 to 2023, with a CAGR of 18.40%. This remarkable growth was mainly attributed to the increase in diabetes incidence globally, the growing understanding of diabetic eye diseases and the screening that followed, and the introduction of new drugs that greatly improved patient outcomes. The sector also witnessed a hike in healthcare expenditure and a passage of reimbursement policies, which made advanced DME treatments more accessible to a wider range of patients.
The forecasted CAGR for 2024 to 2034 is catching up at a very sluggish CAGR of 1.20%. This slowdown is due to the saturation of the market, the high cost of treatment which cuts down affordability, and the possibility of technology stagnation in treatment options. When the market advances, the marginal improvements of existing treatments may not be as revolutionary as in previous years, thereby resulting in a natural slowing of growth rates.
Though the lower CAGR, the global DME market still has untapped potential for expansion. The current research on less invasive and cheaper treatments could help to lift the market. Moreover, the expanding utilization of telemedicine and AI for early diagnosis and management of DME is expected to spur the demand for patient monitoring and adherence, which could lead to a constant demand.
Principal Consultant
The United States is forecast to see a stable expansion in the diabetic macular edema industry. Following the path to market saturation, the United Kingdom and India foresees moderate yet steady momentum through 2034. China and Germany are likely to witness a steady momentum in the diabetic lar edema sector.
| Countries | CAGR 2024 to 2034 |
|---|---|
| United States | 5.8% |
| United Kingdom | 1.1% |
| Germany | 3.2% |
| India | 1.4% |
| China | 4.3% |
The United States is expected to register a CAGR of 5.8% in the forecast period. The country boasts a well-established healthcare infrastructure with relatively high access to advanced diagnostic tools and treatments for DME.
These include advanced imaging technologies for early detection, along with a number of treatment options, from anti-VEGF injections to laser therapy; however, there are still challenges such as the high cost of treatment and barriers to healthcare access for some specific demographic classes that limit optimization of management for DME. Going forward, the USA market may focus on future advances such as gene therapy and sustained-release drug delivery implants that could advance both treatment efficacy and accessibility.
Germany projects a CAGR of 3.2% from the year 2024 to 2034, displaying a tempered growth curve of the DME market. Germany is supported by a very good healthcare system that has a widespread focus on preventive care. This means early diagnoses and a more managed phase of diabetes, possibly reducing the chances of diabetic macular edema development.
Overall, access to some of the new treatments available for DME might be less than in countries like the USA However, Germany is accepting technological advances in diabetic macular edema care. Some of the evolving trends shaping the DME market in Germany are the incorporation of artificial intelligence in early detection and research in gene therapy for possible reversal of DME.
China is expected to register a CAGR of 4.3% from 2024 to 2034. China is a country with a high growth rate of diabetes, which concomitantly raises the number of cases of diabetic macular edema. Another is the increased awareness of DME and its related complications that compel the patients to be in continuous medical care. However, there are some challenges. Infrastructure for healthcare is being developed in some pockets, with China being one of them.
This is another reason advanced diabetic macular edema treatment facilities might not have penetrated certain parts. Yet, China is ready for an active investment in healthcare infrastructure and the adoption of new technologies, as it will cope with the rising diabetes. This, in addition to growing prevalence, makes China one of the main drivers of the global DME market.
Based on drug type, the anti-VEGF segment accounts for a prominent share in 2024. Also, by form, intravitreal injections have come out as the leading segment during the same period.
| Segment | Anti-VEGF (Drug Type) |
|---|---|
| Value Share (2034) | 95.5% |
Anti-VEGF drugs command a share of 95.5% in 2024. The widespread adoption of these drugs is because they work by the selective inhibition of vascular endothelial growth factor (VEGF), which is an active protein in the abnormal growth of blood vessels seen with DME.
In their effective targeting of VEGF, these anti-VEGF drugs reduce leakage from these blood vessels and reduce fluid accumulation in the most important part of the retina, the macula, at the center. This selective reduction ultimately leads to improved vision outcomes for diabetic macular edema patients. Furthermore, the latest anti-VEGF drug formulations have provided improved efficacy and treatment intervals.
The better efficacy in treatment becomes not only better for the patient in terms of compliance and convenience but also reduces pain during intravitreal injections because of their less frequent application.
| Segment | Intravitreal Injections (Form) |
|---|---|
| Value Share (2034) | 94.8% |
Intravitreal injections are currently the leading treatment for DME and have captured 94.8% of the share in 2024. In contrast to drugs given through the oral route, which affects the whole body, the intravitreal route of drug administration allows for a more localized approach.
Intravitreal injections deliver the medication straight into the vitreous cavity of the eye, maximizing the concentration of the drug at the site of action within the macula. Such site-specific drug delivery not only increases drug bioavailability at the target site but also minimizes systemic side effects, usually seen with oral medications, and enhances better tolerability to the patient.
Furthermore, safety and tolerability of intravitreal injections have been improved for patients with DME due to the recent advances in injection techniques and needle designs. Implants and various routes for the delivery of the drug are being researched, but the intravitreal route is still preferred the most since it is the most effective and safe and provides precise therapy at the site of the problem.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some established players like Roche and Novartis are likely to hold dominance in the industry. Biosimilars-structural copies of biologic medications such as anti-VEGFs- are increasingly being seen as a more economical alternative. This might slowly eat into the market share that existing brands enjoy. A one-time treatment that might change the paradigm of DME management is promised by gene therapy, which is on the horizon. In the race to develop active gene therapy candidates, companies like Allergan and Roche could potentially threaten dominance.
To keep a competitive edge, startups must stress on constant development. The established players need to make the already existing formulations of drugs more refined so that the therapy has to be given less frequently, reducing the burden on the patient. They can also think of combination therapies by adding anti-VEGF drugs with other mechanisms that could possibly lead to good outcomes and differentiate them from the rest. Also, one important aspect is likely to be collaboration with research institutions in developing solutions for gene therapy.
Industry Updates
Novartis AG, headquartered in Switzerland, makes strides in diabetic macular edema (DME) treatment as the FDA and EMA accept filings for BEOVU (brolucizumab-dbll), with positive Phase III KESTREL study results.
Bayer AG, based in Germany, receives FDA approval for Eylea, an aflibercept solution for DME treatment, bolstering its portfolio for ocular health.
Allergan Plc., headquartered in Ireland, joins forces with the International Diabetes Federation to forge a global strategy for DME screening, diagnosis, and management.
F. Hoffmann-La Roche Ltd., based in Switzerland, earns FDA approval for Vabysmo (faricimab-svoa) in DME treatment, with promising data from phase III studies on Vabysmo for retinal vein occlusion.
Alimera Sciences Inc., headquartered in the United States, embarks on the NEW DAY clinical trial, evaluating ILUVIEN as a baseline therapy for DME patients.
Segmentation by drug includes anti-VEGF medications such as Ranibizumab (Lucentis) and Aflibercept (Eylea), as well as corticosteroid therapies like Dexamethasone (Ozurdex) and Fluocinolone Acetonide (Iluvien), alongside other off-label drugs.
Classification by form distinguishes between intravitreal injections and intravitreal implants.
Regarding distribution channels, patients may access treatments through hospitals, specialty clinics, or mail order pharmacies.
Geographical segmentation spans across regions including North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa (MEA).
The industry is estimated to surpass USD 4,120.9 million in 2024.
Demand is likely to accelerate at a 1.2% CAGR by 2034.
The industry is set to reach USD 4,642.9 million in 2034.
Novartis AG, Bayer AG, and Allergan Plc. are some prominent names.
Intravitreal injections dominate the industry in 2024.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Pricing Analysis
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
6.1. Drug
6.2. Form
6.3. Distribution Channel
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug
7.1. Anti-VEGF
7.1.1. Ranibizumab (Lucentis)
7.1.2. Aflibercept (Eylea)
7.2. Corticosteroid Therapies
7.2.1. Dexamethasone (Ozurdex)
7.2.2. Fluocinolone Acetonide (Iluvien)
7.3. Others
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Form
8.1. Intravitreal Injections
8.2. Intravitreal Implants
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
9.1. 9.2. Hospitals
9.2. 9.3. Specialty Clinics
9.3. 9.4. Mail Order Pharmacies
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. North America
10.2. Latin America
10.3. Western Europe
10.4. South Asia
10.5. East Asia
10.6. Eastern Europe
10.7. Middle East & Africa
11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. Sales Forecast 2024 to 2034 by Drug, Form, and Distribution Channel for 30 Countries
19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
20. Company Profile
20.1. Novartis AG
20.2. Bayer AG
20.3. Allergan Plc.
20.4. F. Hoffmann-La Roche Ltd.
20.5. Alimera Sciences Inc.
20.6. Valeant Pharmaceuticals International, Inc.
20.7. KalVista Pharmaceuticals
20.8. Genentech
20.9. Oxurion
20.10. Regeneron Pharmaceuticals, Inc.
Explore Healthcare Insights
View Reports
Diabetic Macular Edema Market
